To evaluate somatic alterations associated with clinical resistance of breast cancer to CDK4/6 inhibitor, 36 patients with ER+HER2− MBC received palbociclib and endocrine therapy were included in this study as the discovery cohort (Fig. 1A). Here, ERBB2 is linked to breast cancer.